5-Lipoxygenase
ALOX5protein5-Lipoxygenase produces leukotrienes that regulate inflammatory cell recruitment and resolution post-MI.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleEicosanoid enzyme; inflammation resolution altered post-MI; leukotriene pathway.
Also acts inPlatelet activation
Druggability
DruggableYes
Known drugs / candidates11
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000012779
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I57
C — confounder / Type-II77
A — assay feasibility72
E — evidence strength29
T1DI (composite)8
Specificity differential (R−C)-20.1
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(3)
- Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction.European heart journal · 2026 · PMID 40905492 · doi
- Metabolomics study of the effect of smoking and high-fat diet on metabolic responses and related mechanism following myocardial infarction in mice.Life sciences · 2020 · PMID 33058917 · doi
- Obesity superimposed on aging magnifies inflammation and delays the resolving response after myocardial infarction.American journal of physiology. Heart and circulatory physiology · 2014 · PMID 25485899 · doi
Clinical trials(2)
- Role of the Arachidonate 5-Lipoxygenase Pathway in Coronary Heart DiseaseNCT00379808 · NA · COMPLETED · montelukast, Placebo
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome EventNCT00552188 · PHASE2 · COMPLETED · VIA-2291, Placebo